Prognosis
Lilly CEO Says Covid Will Be ‘Endemic,’ Even With Vaccines: Q&A
- Ricks anticipates even faster development of new antibodies
- Countries will get therapies on basis of need, not wealth
This article is for subscribers only.
Was it a blessing or a curse for Eli Lilly & Co. that President Donald Trump was treated with coronavirus antibodies made by rival Regeneron Pharmaceuticals Inc.?
Neither, according to David Ricks, Lilly’s chief executive officer. What Trump’s treatment did was underscore the critical role of antiviral therapies in combating a disease that, far from being eradicated by new vaccines, is likely to become “endemic,” challenging the public-health system for years to come, Ricks said in an interview for the HLTH virtual conference.